execs

Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech firms look for methods to chop years off R&D timelines and increase the possibilities of success amid rising cost. More than 200...

Early-stage startups working on artificial intelligence, clean technology and B2B software now have one other chunk of capital to go after. After working together at Xerox Corp.’s corporate enterprise capital firm Xerox Ventures, Chris Fisher,...